Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06331299 |
| Consolidated Lead Sponsor | UroGen Pharma |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 99 participants (ACTUAL) |
| Registered Start Date | 2024-08-29 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Loma Linda University Medical Center | Loma Linda, CA | Open Hospital Dossier -> |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis, IN | Open Hospital Dossier -> |
| NYU Langone Health and Perlmutter Cancer Center | New York, NY | Open Hospital Dossier -> |
| Carolina Urologic Research Center | Myrtle Beach, SC | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.